This rural telehealth consultation program named Specialty Care Access Network-Extension for Community Healthcare Outcomes (SCAN-ECHO) was launched by the Department of Veterans Affairs in New Mexico in 2012. To begin with, this program was used for chronic liver disease. This consultation connected rural care teams to specialty clinics, where the patients can be treated in a better way.
A research team at Tufts University revealed that good microbes in gastrointestinal tract could prevent liver inflammation, the major symptom of NAFLD. When the research was conducted on a mice model, they identified two key metabolites produced by the bacteria namely I3A and TA, which could ultimately reduce the severity of NAFLD.
FDA is warning that the liver disease medicine Ocaliva (obeticholic acid) has been incorrectly dosed daily instead of weekly in patients with moderate to severe primary biliary cholangitis (PBC), a rare chronic liver disease, increasing the risk of serious liver injury. To ensure correct dosing and reduce the risk of liver problems, FDA is clarifying the current recommendations for screening, dosing, monitoring, and managing PBC patients with moderate to severe liver disease taking Ocaliva. FDA is adding a new Boxed Warning, FDA’s most prominent warning, to highlight this information in the prescribing information of the drug label. FDA is also requiring a Medication Guide for patients to inform them about this issue.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.